Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ana Gil-Torralvo
Observed names:
A. Gil-Torralvo,
Ana Gil Torralvo,
Gil Torralvo, Ana
Institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario Virgen del Rocío,
Universidad de Sevilla
Observed institutions:
Consejo Superior de Investigaciones Científicas,
Instituto de Biomedicina de Sevilla,
Roche (Spain),
Hospital Universitario Virgen del Rocío,
Universidad de Sevilla
ORCID:
0009-0000-9011-0446
Observed ORCID:
0009-0000-9011-0446
OpenAlex ID:
A5071077919
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
2023
·
Mónica Cejuela
, Ana Gil-Torralvo
, et al.
·
International Journal of Molecular Sciences
·
86
PDF
Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities
2023
·
María A. Domínguez-Cejudo
, Ana Gil-Torralvo
, et al.
·
International Journal of Molecular Sciences
·
44
PDF
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain
2026
·
Alejandro Falcón-González
, Elisenda Llabrés-Valenti
, et al.
·
Frontiers in Oncology
·
2
PDF
Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort
2026
·
R. Garcia-Carbonero
, G.M. Cote
, et al.
·
ESMO Open
·
1
PDF
A Tumor Gene Linked to Treatment Resistance in HER2 Positive Breast Cancer
2026
·
Ana Gil-Torralvo
·
JoLS Journal of Life Sciences
PDF
Exosomal miRNA balance links estrogen receptor signaling to CDK4/6 inhibitor outcomes
2026
·
Maria Angeles Domínguez-Cejudo
, Raquel Chapresto-Garzón
, et al.
·
Research Square
PDF
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer
2026
·
Ana Gil-Torralvo
, M. Ángeles Domínguez-Cejudo
, et al.
·
Breast Cancer
PDF
Abstract P3-12-01: Eribulin in HER2-negative breast cancer. Results of real world data (RWD) in the era of precision oncology
2025
·
Diego Martín Sánchez
, Rocío Pérez Velasco
, et al.
·
Clinical Cancer Research
Caracterización de biomarcadores moleculares de resistencia y sensibilidad a terapia neoadyuvante en cáncer de mama HER2 positivo
2024
·
Gil Torralvo, Ana
·
Deposito de Investigacion Universidad de Sevilla (University of Seville)
Abstract PO1-27-07: Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative
2024
·
Ana Gil-Torralvo
, Yeray Rodriguez
, et al.
·
Cancer Research
Abstract P2-26-17: Establishment of an in vitro preclinical platform: A living biobank of patient-derived organoids with ER+ breast cancer
2023
·
Maria A Dominguez-Cejudo
, Raquel Chapresto
, et al.
·
Cancer Research
Abstract P1-04-18: Identification of UGT2B family genes as potential biomarkers of response to neoadjuvant therapy in HER2+ breast cancer
2023
·
Ana Gil-Torralvo
, Marta Benavent
, et al.
·
Cancer Research
Therapeutic aggressiveness in the oncological patient at the end of life: Experience in a tertiary hospital.
2022
·
Javier Salvador Bofill
, Clara García Grove
, et al.
·
Research Square
PDF
Abstract P2-07-08: Identification of UGT2B15 as a potential biomarker in response to neoadjuvant therapy in HER2+ breast cancer
2022
·
Ana Gil-Torralvo
, Marta Benavent
, et al.
·
Cancer Research
Show more works
View as search
Works count:
14
Citation count:
133
H-index:
2
I10-index:
2
Year
Topic
Type